FDA is issuing this rule to reduce the risk of an outbreak of transmissible spongiform encephalopathy (TSE) in the United States.
The rule is issued by the FDA
mnli hypothesis: The rule is issued by the FDA premise: FDA is issuing this rule to reduce the risk of an outbreak of transmissible spongiform encephalopathy (TSE) in the United States.